Announced Wed, 29 Apr · 12:37 IST
Granules India Q4 & FY26 Results: Standalone PAT up 25%, Revenue Grows 15%
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹703.00
prior close
₹711.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.0+0.4+0.3+2.2-0.3-0.3+1.6+4.7+5.7+7.4+8.8+10.7+13.2—
Up moveDown movePending
AI summary
Granules India reported FY26 standalone revenue of Rs 3,474 cr, up 14.7% YoY, with profit after tax at Rs 401 cr, up 25.4% YoY. Consolidated revenue rose nearly 20% to Rs 5,366 cr with PAT of Rs 595 cr. Q4 standalone PAT was Rs 99 cr on revenue of Rs 877 cr. Board recommended final dividend of Rs 1.75/share. Acquisitions of Senn Chemicals AG and Granules Pharmaceuticals GmbH expanded group footprint. USFDA warning letter on Gagillapur facility was noted.
Likely market impact
Strong 25% PAT growth and acquisitions signal positive momentum; Rs 1.75 dividend rewards shareholders; USFDA overhang on Gagillapur remains a watchpoint.